Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low – Here’s What Happened

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares reached a new 52-week low on Monday . The company traded as low as $30.46 and last traded at $31.97, with a volume of 206071 shares traded. The stock had previously closed at $32.43.

Analyst Ratings Changes

RARE has been the topic of several research reports. Wells Fargo & Company upped their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Piper Sandler cut their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. JPMorgan Chase & Co. raised their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.79.

Ultragenyx Pharmaceutical Stock Down 0.9 %

The firm has a 50 day moving average of $40.83 and a two-hundred day moving average of $45.93. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -5.07 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 14,439 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $607,881.90. Following the sale, the insider now directly owns 107,766 shares of the company’s stock, valued at $4,536,948.60. The trade was a 11.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at $2,358,014.08. The trade was a 5.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock worth $5,256,268 over the last quarter. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Smartleaf Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 493 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $35,000. Human Investing LLC bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $42,000. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 273 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth about $82,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.